Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update

Cover of Publication

Orders exceeding the maximum quantity limit require authorization.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

Download Publication

Advisory: Sublingual & Transmucosal Buprenorphine | pdf (419.86 KB)

Publication Details
Audience(s):
Policymakers, Professional Care Providers, Program Planners, Administrators, & Project Managers, Public Health Professionals
Population Group(s):
People with Substance Use or Abuse Problems as Population Group
Series:
SAMHSA Advisory
Tags:
Buprenorphine, Health Insurance, Medication-Assisted Treatment, Opioid Use Disorder, Opioids or Opiates, Practice Guidelines, Substance Abuse

Publication ID:

SKU:
SMA16-4938

Publication Date:

3/2016

Format:

Advisory

You May Also Be Interested In

Pause

Note: if you experience problems with PDF documents, please download the latest version of Adobe Acrobat Reader®.
Review SAMHSA's public domain notice

Last Updated: 11/07/2018